BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 5791000)

  • 21. [Prognostic factors in the chemotherapy of bronchial cancers].
    Alberto P
    Schweiz Med Wochenschr; 1974 Feb; 104(8):268-71. PubMed ID: 4360755
    [No Abstract]   [Full Text] [Related]  

  • 22. Vincristine (NSC 67574) in non-small cell bronchogenic carcinoma. Results of a phase II clinical study.
    Brugarolas A; Lacave AJ; Ribas A; Miralles MT
    Eur J Cancer (1965); 1978 May; 14(5):501-5. PubMed ID: 348479
    [No Abstract]   [Full Text] [Related]  

  • 23. Evaluation of methotrexate in the treatment of bronchogenic carcinoma.
    Vincent RG; Pickren JW; Fergen TB; Takita H
    Cancer; 1975 Sep; 36(3):873-80. PubMed ID: 1182676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CYTOTOXIC ACTIVITY COMPARED WITH PHOTOMETRIC MEASUREMENTS OF SELECTED ALKYLATING AGENTS.
    SANDERSON RP; MCKENNA JM; BLAKEMORE WS
    Nature; 1965 Jan; 205():479-81. PubMed ID: 14265292
    [No Abstract]   [Full Text] [Related]  

  • 25. [Chemotherapy of the non-small cell bronchogenic carcinoma].
    Dimitriadis K; Boutis L; Tavantzis J; Mouratidou D; Bouchoris N; Koukourikos S; Hatzigogos K; Safarini S
    Onkologie; 1983 Feb; 6(1):8-10. PubMed ID: 6189039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRONCHIAL CARCINOMA TREATED WITH NITROGEN MUSTARD AND CYCLOPHOSPHAMIDE.
    BARRAN KM; HELM WH; KING DA
    Br Med J; 1965 Sep; 2(5463):685-7. PubMed ID: 14337737
    [No Abstract]   [Full Text] [Related]  

  • 27. [VP 16-213 in combination with endoxan, methotrexate and oncovin as polychemotherapy for bronchogenic carcinoma].
    Ryssel HJ; Hasler E; Sonntag RW; Cavalli F; Martin J; Tschopp L; Brunner KW
    Schweiz Med Wochenschr; 1977 Jul; 107(26):912-5. PubMed ID: 877537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bronchogenic carcinoma, stages 3 and 4. Palliation by chemotherapy.
    Roswit B
    JAMA; 1966 Jun; 196(10):848-9. PubMed ID: 4160792
    [No Abstract]   [Full Text] [Related]  

  • 29. Chemotherapy in non-small cell bronchial carcinoma.
    Souhami R
    Thorax; 1985 Sep; 40(9):641-5. PubMed ID: 4060103
    [No Abstract]   [Full Text] [Related]  

  • 30. Adriamycin in advanced bronchogenic carcinoma.
    Cortes EP; Takita H; Holland JF
    Cancer; 1974 Sep; 34(3):518-25. PubMed ID: 4368383
    [No Abstract]   [Full Text] [Related]  

  • 31. Enzyme alterable alkylating agents. XI. Clinical trials of an esterase-susceptible water-soluble agent (S-73) for regional chemotherapy.
    Bakal D; Goodman LE; Ulfohn A; Mamaril AG; Caplan YH; Calle S; Bhagavan BS; Witten B; Williamson CE; Sass S; Seligman AM
    J Surg Res; 1971 May; 11(5):217-23. PubMed ID: 5090338
    [No Abstract]   [Full Text] [Related]  

  • 32. Combination chemotherapy of advanced lung cancer: a randomized trial.
    Hansen HH; Selawry OS; Simon R; Carr DT; van Wyk CE; Tucker RD; Sealy R
    Cancer; 1976 Dec; 38(6):2201-7. PubMed ID: 187312
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monochemotherapy of bronchogenic carcinoma withs special reference to cell type.
    Selawry OS
    Cancer Chemother Rep 3; 1973 Mar; 4(2):177-88. PubMed ID: 4277763
    [No Abstract]   [Full Text] [Related]  

  • 34. Ifosfamide: a weekly dose fractionated schedule in bronchogenic carcinoma.
    Morgan LR; Posey LE; Rainey J; Bickers J; Ryan D; Vial R; Hull EW
    Cancer Treat Rep; 1981; 65(7-8):693-5. PubMed ID: 6265084
    [No Abstract]   [Full Text] [Related]  

  • 35. [Progress observations in patients with inoperable lung tumors during treatment with a combined internal therapy (alkylating agent and endogenous polypeptid)].
    Klose G; Below R
    Krebsarzt; 1969; 24(2):80-7. PubMed ID: 5802199
    [No Abstract]   [Full Text] [Related]  

  • 36. Chemotherapy of inoperable bronchogenic carcinoma.
    Behera D; Malik SK
    Indian J Chest Dis Allied Sci; 1985; 27(3):175-89. PubMed ID: 3017850
    [No Abstract]   [Full Text] [Related]  

  • 37. Modulation of the toxicity and antitumour activity of alkylating drugs by steroids.
    Shepherd R; Harrap KR
    Br J Cancer; 1982 Mar; 45(3):413-20. PubMed ID: 7073935
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical experiences with dibromodulcitol (NSC-104800) in solid tumors.
    Phillips RW; Brook J
    Cancer Chemother Rep; 1971 Dec; 55(5):567-73. PubMed ID: 4946081
    [No Abstract]   [Full Text] [Related]  

  • 39. [The mechanism of tumor drug resistance].
    Kulik GI
    Vopr Onkol; 1969; 15(11):60-4. PubMed ID: 5368841
    [No Abstract]   [Full Text] [Related]  

  • 40. Chemotherapy of induced skin tumors in mice.
    Sugiura K
    Gan; 1968 Oct; 59(5):367-76. PubMed ID: 4179170
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.